Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC: pembrolizumab with carbon ion radiotherapy in metastatic or unresectable melanoma
2020-003680-25Phase 2Active
- Sponsor
- Fondazione Centro Nazionale di Adroterapia Oncologica
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in melanoma, sponsored by Fondazione Centro Nazionale di Adroterapia Oncologica. Primary endpoint: Objective response rate according to RECIST. Started Jun 2021; status: active.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2020-003680-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003680-25.